The destruction of immunosuppressive cells is accompanied by the release of pro-inflammatory ... direct the immune system to target tumor cell-specific antigens, the T-win approach elicits a ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to ...

The vaccine is slated for public release in early 2025 and will ... enable the body’s cells to produce a specific cancer protein, known as an antigen. This process trains the immune system ...

A new paper by a team of Concordia researchers from the departments of Biology and Physics proposes a novel method of ...

CAR-M are activated by tumor-associated antigen engagement with the CAR, signaling via CD3-ζ to phagocytose the tumor cell and release cytokines and chemokines that ‘warm up’ the tumor ...

Researchers have designed process that uses ultrasound to modify the behavior of cancer-fighting T cells by increasing their cell permeability. They targeted freshly isolated human immune cells with ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits.

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets the immune checkpoint B7-H3 for diffuse intrinsic pontine glioma, or DIPG, ...